Iron Mountain Inc vs 10X Genomics Inc — how do they compare? Iron Mountain Inc trades at $124.34 (market cap $36.44B), while 10X Genomics Inc trades at $57.74 (market cap $7.61B). The key difference: Iron Mountain Inc is far larger — about 4.8× 10X Genomics Inc's market cap, and Iron Mountain Inc pays a 2.82% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| IRM | TXG | |
|---|---|---|
Market Cap | $36.44B | $7.61B |
Sector | Real Estate | Health |
52-Week High | $133.06 | $58.57 |
52-Week Low | $78.86 | $11.34 |
Enterprise Value | $55.85B | $7.14B |
Dividend Yield | 2.82% | — |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $121.56, up 0.34% today, with strong earnings beats in recent quarters and a bullish analyst consensus price target of $141.50. The stock shows bearish technical signals but benefits from robust revenue growth, particularly in data centers and digital solutions, though high debt levels and declining profit margins pose challenges. Recent news highlights CEO stock sales and institutional buying activity.
Outlook: IRM offers growth potential from data center expansion and recurring revenue streams, supported by positive analyst ratings. Key risks include elevated debt, margin pressure, and competitive threats. Investors should weigh strong operational performance against financial leverage and market sentiment shifts for balanced decision-making.
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
Trailing returns across standard periods
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →